MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Schrodinger Inc

Geschlossen

BrancheGesundheitswesen

11.33 -1.22

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.19

Max

11.34

Schlüsselkennzahlen

By Trading Economics

Einkommen

169M

136M

Verkäufe

33M

87M

EPS

-0.18

Gewinnspanne

155.644

Angestellte

850

EBITDA

67M

36M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.05% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

24M

850M

Vorheriger Eröffnungskurs

12.55

Vorheriger Schlusskurs

11.33

Nachrichtenstimmung

By Acuity

50%

50%

185 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Schrodinger Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2026, 17:04 UTC

Wichtige Markttreiber

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. Apr. 2026, 00:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Big Yachts, Big Bucks -- Barrons.com

10. Apr. 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. Apr. 2026, 21:01 UTC

Ergebnisse

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. Apr. 2026, 20:50 UTC

Market Talk
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

10. Apr. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Apr. 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. Apr. 2026, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. Apr. 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. Apr. 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. Apr. 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. Apr. 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. Apr. 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. Apr. 2026, 18:25 UTC

Market Talk
Wichtige Nachrichtenereignisse

Precious Metals Finish With Weekly Gains -- Market Talk

10. Apr. 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. Apr. 2026, 17:31 UTC

Market Talk
Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. Apr. 2026, 17:26 UTC

Ergebnisse

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. Apr. 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. Apr. 2026, 17:00 UTC

Wichtige Nachrichtenereignisse

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. Apr. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. Apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. Apr. 2026, 16:12 UTC

Ergebnisse

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. Apr. 2026, 16:11 UTC

Ergebnisse

Partners Group: Traditional Programs Contributed $3.3B

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group 1Q New Client Demand $8.3B

10. Apr. 2026, 16:09 UTC

Ergebnisse

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. Apr. 2026, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Plenitude Completes Acquisition of Acea Energia

10. Apr. 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Schrodinger Inc Prognose

Kursziel

By TipRanks

54.05% Vorteil

12-Monats-Prognose

Durchschnitt 17.67 USD  54.05%

Hoch 20 USD

Tief 13 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Schrodinger Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

23.27 / 26.13Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Very Strong Bullish Evidence

Stimmung

By Acuity

185 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat